2016
DOI: 10.1016/j.juro.2016.02.1698
|View full text |Cite
|
Sign up to set email alerts
|

Mp74-01 a Randomized, Double-Blind, Placebo Controlled Study of 2 Doses of Ser120 (Low Dose Desmopressin) Nasal Spray in Patients With Nocturia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…These preclinical findings of low‐dose and gender specific formulation have been clinically confirmed in two trials . The low‐dose safety has been confirmed in a conference abstract from Kaminetsky et al using a nasal spray formulation, but not the gender. Larger comparative pharmacokinetic and pharmacodynamics studies are needed to explain the difference in findings.…”
Section: Treatment Of Nocturia Based On Causative Packagesmentioning
confidence: 74%
“…These preclinical findings of low‐dose and gender specific formulation have been clinically confirmed in two trials . The low‐dose safety has been confirmed in a conference abstract from Kaminetsky et al using a nasal spray formulation, but not the gender. Larger comparative pharmacokinetic and pharmacodynamics studies are needed to explain the difference in findings.…”
Section: Treatment Of Nocturia Based On Causative Packagesmentioning
confidence: 74%
“…Noctiva is a newly FDA-approved nasal spray which consists of desmopressin acetate and has been approved for treatment of nocturia. A randomized controlled phase 3 study which did not exclude men who had concomitant BPH (about 30%) showed that desmopressin acetate was well tolerated and resulted in significant efficacy in treatment of nocturia compared to placebo [74]. Nocdurna is another form of desmopressin recently approved for treatment of nocturia in the majority of EU countries.…”
Section: Desmopressinmentioning
confidence: 99%
“…The article only discussed 1 primary efficacy end point of the 2 phase 3 trials . It did not mention secondary efficacy end points, such as quality-of-life (QOL) measures.…”
mentioning
confidence: 99%